A horse therapy program in Namibia brings joy to children with learning disabilities
De Meyer runs a program in the southern African country of Namibia that harnesses the power but also the gentleness of horses to help children with learning disabilities and conditions like ADHD and autism.
Each weekday morning, de Meyer's dusty paddock just outside the capital, Windhoek, is enlivened by a group of eight to 10 children from one of the special schools she helps. The children ride the horses, groom them, stroke them and often, de Meyer says, talk to them.
De Meyer grew up on a farm surrounded by horses and they've always been part of her life. She said they have a quality that is invaluable: They don't judge the children, no matter how different they are.
'The horse is the hero in this whole situation because these kids don't want to be around a lot of people," de Meyer said.
De Meyer's program, "Enabling Through the Horse," is supported by the Namibian Equestrian Federation and won an award last year from the International Equestrian Federation because it 'underlines the wonderful characteristics of the horse in exuding sensitivity and intuition.'
Horse therapy has been promoted by autism groups and those that work with children with learning disabilities as having a positive impact. And animal therapy in general has been found to be useful in many instances, like dogs that help military veterans with post-traumatic stress disorder and therapy cats that are taken to hospitals and nursing homes.
Some survivors of the devastating 2023 Hawaii wildfires found relief in horse therapy while grieving loved ones they had lost.
De Meyer jokes she has 'two-and-a-half horses.' These include two Arabians — a white mare named Faranah and a brown gelding, Lansha — while the 'half' is a miniature horse called Bonzi, who is about head-high for a 5-year-old.
The Arabians are often the most useful for the children's therapy because of their size, de Meyer said.
'It gives them self-esteem. When they stroke the horse, the therapy starts because this is a very big animal compared to their height, and they are not scared to stroke the horse ... and then to ride it and tell the horse what they want,' she said.
De Meyer works with children with a range of conditions or disabilities, including autism, attention-deficit/hyperactivity disorder, Down syndrome, those who are nonverbal or touch sensitive, and some who were born with fetal alcohol syndrome and have developmental problems.
She has received interest from other countries in Africa and Asia to start similar programs there.
'The changes that I've seen with the learners are significant,' said Chriszell Louw, a teacher at Dagbreek School, which says it is one of just two government schools in Namibia for children with intellectual disabilities. 'We have a learner that likes to talk a lot. When we come here, she knows she has to keep quiet. She sits in her place.'
"Some of them you see they are more open, they are happy. Some of them were very scared when they started with the horse riding but now they are very excited. When they hear we're going to the horses they are very excited and just want to go by themselves,' Louw said.
De Meyer said her program helps with fine-motor skills, gross-motor skills, muscle strengthening, coordination, balance and posture, all important for kids who struggle to sit at a desk at school and learn.
One simple exercise de Meyer has children do when they ride is to let go of the reins and stretch their arms out straight and to the sides, using only their torso and lower body to balance as a groom leads the horse around the paddock.
Some of the kids break out in smiles when they let go and look like they're soaring.
"We make the world different for these kids," de Meyer said.
___
For more on Africa and development: https://apnews.com/hub/africa-pulse
___
The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
4 hours ago
- San Francisco Chronicle
Scientists say they have solved the mystery of what killed more than 5 billion sea stars
WASHINGTON (AP) — Scientists say they have at last solved the mystery of what killed more than 5 billion sea stars off the Pacific coast of North America in a decade-long epidemic. Sea stars – often known as starfish – typically have five arms and some species sport up to 24 arms. They range in color from solid orange to tapestries of orange, purple, brown and green. Starting in 2013, a mysterious sea star wasting disease sparked a mass die-off from Mexico to Alaska. The epidemic has devastated more than 20 species and continues today. Worst hit was a species called the sunflower sea star, which lost around 90% of its population in the outbreak's first five years. 'It's really quite gruesome,' said marine disease ecologist Alyssa Gehman at the Hakai Institute in British Columbia, Canada, who helped pinpoint the cause. Healthy sea stars have 'puffy arms sticking straight out,' she said. But the wasting disease causes them to grow lesions and 'then their arms actually fall off.' The culprit? Bacteria that has also infected shellfish, according to a study published Monday in the journal Nature Ecology and Evolution. The findings 'solve a long-standing question about a very serious disease in the ocean," said Rebecca Vega Thurber, a marine microbiologist at University of California, Santa Barbara, who was not involved in the study. It took more than a decade for researchers to identify the cause of the disease, with many false leads and twists and turns along the way. Early research hinted the cause might be a virus, but it turned out the densovirus that scientists initially focused on was actually a normal resident inside healthy sea stars and not associated with disease, said Melanie Prentice of the Hakai Institute, co-author of the new study. Other efforts missed the real killer because researchers studied tissue samples of dead sea stars that no longer contained the bodily fluid that surrounds the organs. But the latest study includes detailed analysis of this fluid, called coelomic fluid, where the bacteria Vibrio pectenicida were found. 'It's incredibly difficult to trace the source of so many environmental diseases, especially underwater,' said microbiologist Blake Ushijima of the University of North Carolina, Wilmington, who was not involved in the research. He said the detective work by this team was 'really smart and significant.' Now that scientists know the cause, they have a better shot at intervening to help sea stars. Prentice said that scientists could potentially now test which of the remaining sea stars are still healthy — and consider whether to relocate them, or breed them in captivity to later transplant them to areas that have lost almost all their sunflower sea stars. Scientists may also test if some populations have natural immunity, and if treatments like probiotics may help boost immunity to the disease. Such recovery work is not only important for sea stars, but for entire Pacific ecosystems because healthy starfish gobble up excess sea urchins, researchers say. Sunflower sea stars 'look sort of innocent when you see them, but they eat almost everything that lives on the bottom of the ocean,' said Gehman. 'They're voracious eaters.' With many fewer sea stars, the sea urchins that they usually munch on exploded in population – and in turn gobbled up around 95% of the kelp forest s in Northern California within a decade. These kelp forests provide food and habitat for a wide variety of animals including fish, sea otters and seals. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
New York Post
6 hours ago
- New York Post
Japan's oldest person is a 114-year-old retired doctor who carried an Olympic torch in 2021
Shigeko Kagawa, a 114-year-old retired physician from Nara Prefecture, has become Japan's oldest living person, following the death of 114-year-old Miyoko Hiroyasu, according to Japan's Ministry of Health, Labor and Welfare. Kagawa, a symbol of Japan's extraordinary longevity, graduated from medical school before World War II, served at a hospital in Osaka during the war, and later ran her family's clinic as an obstetrician and gynecologist. She retired at 86. At 109, Kagawa became one of the oldest torchbearers in Olympic history during the Tokyo 2021 torch relay. Advertisement Shigeko Kagawa, a 114-year-old retired physician from Nara Prefecture, has become Japan's oldest living person. AP She is not doing anything out of the ordinary to stay healthy, a local television MBS News, said last week, quoting her family. She keeps a regular routine, going to bed and waking up at set times, and she eats small portions but always has three proper meals a day. Her predecessor as Japan's oldest person led a similarly active life. Born in 1911, Hiroyasu studied art in Tokyo, taught in Hiroshima Prefecture, and raised three children. She died in a nursing home in Oita Prefecture, where she spent her days reading newspapers, sketching, and playing card games. Advertisement 'I am grateful to be healthy,' she said on her 113th birthday. Despite an overall population decline, Japan's elderly population continues to grow. As of September 1, 2024, a record 36 million people — 29% of the population — were aged 65 or older, the highest proportion of seniors in the world. At 109, Kagawa became one of the oldest torchbearers in Olympic history during the Tokyo 2021 torch relay. AP Advertisement Those aged 80 and above now make up 10% of the population, according to the Ministry of Internal Affairs and Communications. There are 95,119 centenarians across the country.
Miami Herald
7 hours ago
- Miami Herald
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. "This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world." said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. "This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV," said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. "We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality," said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. "We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership," said Stefano Colloca, CEO and co-Founder of ReiThera. "This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions." Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala TrustTheodorah Rirhandzu Ndzhukule, DTHFLimakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeirahteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI
